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Abstract
The main regulators of leukocyte trafficking during inflammatory responses are chemokines.
However, another class of recently identified chemotactic agents is extracellular cyclophilins, the
proteins mostly known as receptors for the immunosuppressive drug, cyclosporine A. Cyclophilins
can induce leukocyte chemotaxis in vitro and have been detected at elevated levels in inflamed tissues,
suggesting that they might contribute to inflammatory responses. We recently identified CD147 as
the main signaling receptor for cyclophilin A. In the current study we examined the contribution of
cyclophilin-CD147 interactions to inflammatory responses in vivo using a mouse model of acute
lung injury. Blocking cyclophilin-CD147 interactions by targeting CD147 (using anti-CD147 Ab)
or cyclophilin (using nonimmunosuppressive cyclosporine A analog) reduced tissue neutrophilia by
up to 50%, with a concurrent decrease in tissue pathology. These findings are the first to demonstrate
the significant contribution of cyclophilins to inflammatory responses and provide a potentially novel
approach for reducing inflammation-mediated diseases.
Leukocyte trafficking and recruitment are critical processes in host immune surveillance as
well as for inflammation-mediated pathology. The main regulators of leukocyte trafficking are
chemokines, a family of chemoattracting cytokines. Another, less appreciated, class of
chemotactic agents is cyclophilins, a group of highly abundant cellular proteins, mostly known
as receptors for the immunosuppressive drug, cyclosporine A (CsA).3 Cyclophilin A (CyPA)
is a ubiquitously distributed intracellular protein belonging to the cyclophilin family. However,
during the course of inflammatory responses, CyPA is released into extracellular tissue spaces
by both live and dying cells (1–3). Indeed, elevated levels of CyPA have been reported in
several different inflammatory diseases, including sepsis, rheumatoid arthritis, and vascular
smooth muscle cell disease (2,4,5). In the case of rheumatoid arthritis, a direct correlation
between levels of CyPA and the number of neutrophils in the synovial fluid of rheumatoid
arthritis patients was reported (5). In vitro studies have shown that extracellular CyPA is a
potent chemoattractant for human monocytes, neutrophils, eosinophils, and T cells (6–8).
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Furthermore, CyPA can induce a rapid inflammatory response, characterized by neutrophil
influx, when injected in vivo (1).
Previous studies have shown that the primary binding site for extracellular cyclophilins is cell
surface heparans (9,10). However, we recently identified CD147, a type I transmembrane
protein belonging to the immunophilin family, as the main signaling receptor for extracellular
CyPA and have shown that the presence of CD147 is essential for cyclophilin-mediated
chemotaxis and signaling to occur in human leukocytes (6). Based on all the above findings,
we have proposed that CyPA-CD147 interactions might contribute directly to leukocyte
recruitment during inflammatory responses and therefore might contribute to the pathogenesis
of certain inflammatory diseases (11). Although several studies have explored CyPA-CD147
interactions using in vitro approaches (6,8), the physiological and pathological significance of
these interactions has not been investigated. Thus, in the current study we have examined
CyPA-CD147 interactions in vivo after the induction of an inflammatory response.
Specifically, we used a mouse model of acute lung inflammation that closely resembles acute
lung injury (ALI) in humans. The model is characterized by increased capillary permeability,
interstitial and alveolar edema, and an influx of circulating inflammatory cells, predominantly
neutrophils, into lung tissues and airways after intranasal administration of LPS (12). Our
findings demonstrate that CyPA-CD147 interactions do indeed contribute to the recruitment
of neutrophils into tissues during an inflammatory response. Furthermore, we show that
blocking these interactions significantly inhibits neutrophil influx into inflamed tissues,
providing a potentially novel therapeutic approach for the alleviation of inflammation-
mediated diseases.
Materials and Methods
Animals
Male C57BL/6 mice, 8 wk or older, were used to obtain peritoneal neutrophils. For all other
studies, female C57BL/6 mice, 6–8 wk old, were used. All mice were purchased from the
National Cancer Institute animal facility. All studies were reviewed and approved by the
institutional animal care and use committee at George Washington University Medical Center.
Abs and reagents
Anti-mouse CD147 was purified from the RL73.2 hybridoma (13). The rat IgG2a hybridoma
(HB-189) was obtained from American Type Culture Collection and was used as a source of
isotype control mAb. Both Abs were purified by the National Cell Culture Center. FITC-
conjugated F(ab′)2 anti-rat IgG was purchased from Jackson ImmunoResearch Laboratories.
PE-conjugated anti-mouse GR-1 was purchased from BD Biosciences. Anti-human
cyclophilin A mAb (cross-reacts with murine cyclophilin A) was obtained from U.S.
Biological, and HRP-conjugated antirabbit secondary Ab was purchased from Amersham
Biosciences. LPS (Escherichia coli serotype 055:B5) and FMLP were obtained from Sigma-
Aldrich. Human recombinant CyPA, which differs from mouse CyPA by only one amino acid
residue, was purchased from Calbiochem. The non-immunosuppressive CsA drug,
SDZNIM811, was a gift from B. Willi (Novartis Pharma, Vienna, Austria). The drug powder
was dissolved in 100% ethanol and sequentially diluted into 50%, then 20%, ethanol, followed
by a 1/1 dilution in PBS.
Analysis of CD147 expression on leukocytes
Levels of CD147 expression were compared on different leukocyte and neutrophil populations
by FACS analysis. Leukocytes were stained with 1 µg of anti-mouse CD147 or isotype control
mAb, followed by FITC-conjugated anti-rat IgG for detection. In some experiments, PE-
conjugated anti-GR-1 was added after the second step.
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Neutrophil enrichment
Circulating neutrophils were enriched from mouse peripheral blood collected by cardiac
puncture. The collected blood was treated with ACK lysing buffer (Quality Biological) to
remove RBC. Peritoneal neutrophils were isolated from the peritoneal cavity of mice 3 h after
an i.p. injection of 1 ml of 3% thioglycolate broth. The isolated peritoneal cells were washed
three times in cold PBS and were overlaid onto a sequential gradient of Histopaque-1007 and
-1119 (Sigma-Aldrich). The enriched (>80%) neutrophils were collected from the interface of
the two Histopaque layers. Neutrophils from inflamed tissue were obtained from minced lung
tissue 18 h after intranasal delivery of 2 µg of LPS (see below). Lung tissue cells were treated
with ACK lysing buffer to remove RBC, yielding a >60% enriched population of neutrophils.
Chemotaxis assays
All chemotaxis assays were conducted using peritoneal neutrophils. The assays were set up
using 48-well modified Boyden chambers (Neuro Probe) with the two compartments separated
by a 5-µm polycarbonate membrane (NeuroProbe). Neutrophils (104 cells/well) in RPMI 1640
culture medium supplemented with 1% BSA were added to the upper compartments, whereas
media containing different dilutions of recombinant CyPA or FMLP (to provide a positive
control for chemotactic responses) or medium alone were added to the lower wells. For all
studies, we used a dose of 10−7 M FMLP, which in our hands induces optimal neutrophil
migration. For blocking experiments, different doses of anti-CD147 mAb, isotype control
mAb, or CsA drug were included in both the upper and lower compartments. The chambers
were incubated at 37°C in 5% CO2 for 45 min, after which the membrane was removed, the
nonmigrated cells were scraped off, and the membranes were stained with Wright-Giemsa
(CAMCO) to discriminate neutrophils. A chemotactic index was calculated for each test well
by dividing the number of cells counted for that well by the number of cells counted in medium
wells. In previous studies, we and others have confirmed that the observed leukocyte migration
induced by extracellular cyclophilins is due to chemotaxis and not to an increase in
chemokinesis (1,6–8).
Regimens for inducing LPS-induced ALI and its inhibition
For the induction of acute lung inflammation, C57BL/6 mice were given 2 µg of LPS in 50 µl
of PBS intranasally under light anesthesia (halothane). In some experiments, control groups
of mice received 50 µl of PBS alone. For the in vivo blocking experiments using anti-CD147,
groups of mice received i.p. injections of 100 µg of anti-CD147 or isotype control Ab on days
1 and 0 before intranasal delivery of LPS. For the in vivo blocking experiments using
SDZNIM811, mice were given an i.p. injection of drug (20 mg/kg body weight) or diluent
alone; 10 h later, the mice were given a second i.p. dose, followed immediately by intranasal
delivery of LPS. In some experiments, groups of mice were given a combination of the two
treatments, with the same dosages and kinetics as those used for the individual treatments. All
animals were killed 18 h after intranasal delivery of LPS by exposure to carbon dioxide.
Bronchoalveolar lavage (BAL) and tissue harvesting
After the animals were killed, lung airway cells were collected from individual mice by BAL,
in which a cannula was inserted into the trachea, and three 1-ml washes of cold PBS were
infused in and out of the airways. Lungs were then perfused via the right ventricle with 20 ml
of ice-cold PBS. Perfused lungs were finely chopped and incubated at 37°C for 20 min in 5 ml
of a digestion mixture consisting of Click’s medium (BioSource International), 5% FCS, 150
U/ml collagenase type IV (Worthington Biochemical), and 20 µg/ml DNase I (ICN
Biomedicals). Digested tissues were then pushed through a metal strainer, followed by a nylon
mesh screen, to generate single-cell suspensions. Both BAL cells and lung tissue suspensions
were treated with ACK lysing buffer to remove RBC and then counted. Individual cell
Arora et al. Page 3
J Immunol. Author manuscript; available in PMC 2010 May 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
suspensions were stained with PE-conjugated anti-GR-1 to establish the numbers of neutrophils
present after the different regimens.
Western blot analysis of BAL fluid
For Western blot studies, a single 1-ml ice-cold PBS wash was used for the BAL procedure.
BAL fluids were then cleared of leukocytes by centrifugation and pooled within experimental
groups of mice. Equivalent volumes (20 µl) of each pool were separated by SDS-PAGE under
reducing conditions. A lysate of HEK293T cells was used as a positive control for the detection
of CyPA. Separated proteins were then transferred onto an Immun- Blot polyvinylidene
difluoride membrane (Bio-Rad). After blocking in 10% milk, the presence of CyPA was
detected by incubating membranes in rabbit anti-human CyPA mAb, followed by HRP-
conjugated, anti-rabbit secondary Ab. Detection was conducted using ECL (Amersham
Biosciences).
Histology
The lungs were first perfused with 20 ml of ice-cold PBS via the right ventricle, then 1 ml of
10% formalin was infused into the trachea to inflate and fix the lung tissue. The trachea was
tied off using suture thread, and the fixed lungs were isolated and stored in 10% formalin until
further processing. Fixed organs were embedded in paraffin, and 5-µm sections were cut and
stained with H&E to identify changes in cell composition (Histoserv).
Results
CD147 is expressed on murine neutrophils
Although CD147 expression is well characterized on human leukocytes, little is known of its
expression on murine cells. In the current study the expression of CD147 on PBL of C57BL/
6 mice was examined by flow cytometric analysis. As shown in Fig. 1A, CD147 was readily
detected on all three major subsets of leukocytes, with the highest levels expressed by
granulocytes. Focusing our analysis on neutrophils, the elevated level of CD147 was confirmed
to be present on both circulating neutrophils as well as neutrophils obtained from tissues,
including the peritoneal cavity and inflamed lung tissue (Fig. 1B).
Murine neutrophils migrate in response to CyPA in vitro
To test the capacity of murine neutrophils to migrate in response to CyPA, in vitro chemotaxis
assays were conducted using Boyden chambers. As shown in Fig. 2A, murine neutrophils
readily migrated in response to recombinant CyPA. The response was dose dependent and
demonstrated the characteristic bell-shaped curve typical of other chemotactic factors. Based
on these data, a 100 ng/ml concentration of CyPA was used for subsequent studies. Having
established the capacity of CyPA to induce chemotaxis of murine neutrophils, we next
confirmed that this response was CD147 dependent. In initial studies testing different doses of
anti-CD147 mAb (data not shown), we determined that a 25 µg/ml dose provided maximal
inhibition of CyPA-mediated migration. Indeed, this dose of anti-CD147 mAb inhibited CyPA-
dependent neutrophil chemotaxis by >90% relative to an equivalent concentration of isotype
control mAb or no Ab (Fig. 2B). In a separate study we confirmed that the observed CyPA-
mediated chemotaxis of murine neutrophils could also be blocked using CsA, a known inhibitor
of cyclophilin function. Specifically, we made use of a nonimmunosuppressive analog of CsA,
SDZNIM811, which has been reported to induce structural changes in CyPA, thereby inhibiting
its activity without affecting calcineurin (14). As shown in Fig. 2C, the extent of inhibition of
CyPA-mediated neutrophil migration by a previously optimized dose (2 µM) of SDZNIM811
was equivalent to that induced by anti-CD147 mAb. Of importance, neither anti-CD147 nor
Arora et al. Page 4
J Immunol. Author manuscript; available in PMC 2010 May 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
CsA had any effect on FMLP-induced migration of neutrophils (Fig. 2C), demonstrating that
both types of inhibition were specific for CyPA-CD147 interactions.
Blocking CyPA-CD147 interactions significantly reduces LPS-induced lung inflammation
Our final series of studies were designed to establish whether blocking CyPA-CD147
interactions has an effect on inflammatory responses in vivo. For these studies we used a mouse
model of acute lung inflammation that closely resembles human ALI. The LPS mouse model
of ALI has been previously described and characterized by other groups (15). In this model,
LPS is given by intranasal delivery to C57BL/6 mice, resulting in a rapid induction of several
proinflammatory cytokines and chemokines as well as a major accumulation of neutrophils in
lung tissues and airways within 12–24 h. The data in Fig. 3 show that this model of LPS-induced
lung inflammation is also associated with an increase in CyPA protein. Indeed, Western blot
analysis conducted on BAL fluid from groups of mice treated with LPS showed a striking
increase in extracellular CyPA compared with that from groups of mice that were given PBS
alone (Fig. 3A). Densitometric analysis of the protein bands showed the increases in CyPA to
be statistically significant (Fig. 3B) and to correlate closely with the elevated numbers of
neutrophils present within BAL samples (Fig. 3C).
Having established the presence of elevated CyPA and elevated numbers of neutrophils in our
model of LPS-induced tissue inflammation, we next tested the capacity of anti-CD147
treatment to affect this inflammation. Thus, mice were given an i.p. injection of 100 µg of anti-
CD147 mAb (or isotype control mAb) 1 day before intranasal delivery of LPS and a second
i.p. injection on the same day as intranasal LPS. All mice were killed 18 h later, and their tissue
and BAL leukocytes were enumerated by flow cytometry. Fig. 4A shows the mean number of
neutrophils recovered from the lung tissues and airways of each group of mice. Strikingly, anti-
CD147 treatment reduced neutrophil infiltration by 40–50% (relative to isotype control) at both
tissue sites. Both these reductions were statistically significant (p < 0.05), with no significant
difference between isotype control and untreated groups. The decrease in neutrophilia by anti-
CD147 treatment was also observed at the histological level (Fig. 4B). Specifically, the number
and severity of inflammatory foci around lung airways and blood vessels were greatly reduced
after anti-CD417 treatment. Finally, we tested whether blocking the CyPA arm of CyPA-
CD147 interactions could also reduce neutrophil infiltration in this model of acute tissue
inflammation. As with our in vitro studies, we made use of the nonimmunosuppressive drug,
SDZNIM811. For the in vivo blocking studies, mice received a 20 mg/kg body weight dose
of the drug (or diluent alone) i.p.; 10 h later they received a second i.p. dose of the drug along
with intranasal delivery of LPS. The data in Fig. 5A show that, as observed with anti-CD147
treatment, blocking CyPA significantly (p < 0.05) reduced neutrophil infiltration into tissues
with ongoing inflammation. There was no significant difference between diluent control and
untreated groups. We also tested whether combining anti-CD147 and SDZNIM811
intervention regimens might lead to a greater reduction in neutrophilia during lung
inflammation. As shown in Fig. 5B, although the individual treatments led to reductions in the
total number of tissue neutrophils ranging from 29% (SDZNIM811 alone) to 38% (anti-CD147
alone), combining the two treatments reduced neutrophil numbers by only an additional 6%
compared with the effect of anti-CD147 treatment. Although each of the observed reductions
in neutrophil numbers was statistically significant relative to the untreated group, there were
no significant differences between treatment groups. Taken together, these findings suggest
that all three regimens inhibited neutrophil influx into tissues to a similar extent, and that anti-
CD147 and SDZNIM811 intervention regimens are probably acting on the same cyclophilin-
CD147 interactions.
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Discussion
One of the hallmarks of inflammation is the extravasation of neutrophils. Although chemotactic
factors, including IL-8/CXCL8, platelet-activating factor, and TNF-α, are known to be
involved in the mobilization of neutrophils by generating a chemical gradient within the site
of inflammation, indirect evidence provided by several disease models shows that extracellular
cyclophilins might also be a contributing factor to the establishment of inflammatory
pathology. The goal of the current study was to establish the contribution of cyclophilin-
mediated recruitment of leukocytes, specifically neutrophils, into tissues during inflammatory
responses. Although cyclophilin-induced recruitment of neutrophils and T lymphocytes has
previously been studied in vitro, this is the first attempt to understand the physiological and
pathological significance of cyclophilin-CD147 interactions in vivo.
As part of these studies, we demonstrated CD147 expression on circulating murine leukocytes
and observed that granulocytes/neutrophils expressed the highest levels. Interestingly, this
expression was slightly decreased on tissue neutrophils compared with circulating neutrophils.
One potential explanation is that CD147 expression is down-regulated on leukocytes after their
entry into tissues, supporting the idea that CD147 is most important for the recruitment phase
of leukocytes during an inflammatory response. However, other studies have reported elevated
levels of CD147 on leukocytes present within inflammatory sites, including fibroblastlike cells
and granulocytes in the synovial joints of rheumatoid arthritis patients (16,17). Whether these
differences in expression contribute in any way to the recruitment and/or entry of leukocytes
into tissues has not been established; however, using in vitro chemotaxis assays, we have
observed no difference in the capacity of neutrophils from the circulation vs different tissues
to migrate in response to CyPA (K. Arora, unpublished observations).
Our in vitro studies clearly demonstrate the capacity of CyPA to induce neutrophil migration.
Furthermore, the importance of CD147 to this CyPA-specific chemotaxis was confirmed by
the >90% inhibition of the response using anti-CD147 Ab. Most importantly, our studies also
demonstrate a role for cyclophilin-CD147 interactions during an inflammatory response. The
LPS mouse model of ALI has been previously described and characterized by other groups,
and several proinflammatory cytokines and chemokines have been reported to be present within
the pulmonary tract of these mice (15). In the current study we now show that this model of
lung inflammation is also associated with elevated levels of CyPA. Such findings agree well
with other studies of inflammation-mediated diseases in which elevated levels of extracellular
cyclophilins were detected in the synovial fluid of rheumatoid arthritis patients (5) and in the
serum of patients with ongoing sepsis (4). Strikingly, treatment of the LPS-sensitized mice
with anti-CD147 Ab led to a 40–50% inhibition of the development of neutrophilia within lung
tissues and airways. This decrease in neutrophil accumulation within tissues was also observed
at the histological level, with a greatly reduced number of inflammatory foci present in mice
treated with anti-CD147. Additional confirmation of the contribution of cyclophilin-CD147
interactions to neutrophilia during inflammatory responses was provided by treating mice with
an inhibitor to the cyclophilin arm of the interaction. Treatment with SDZNIM811, a
nonimmunosuppressive CsA analog, inhibited neutrophil influx into lung tissues to a similar
extent as observed with anti-CD147. Interestingly, treating mice with a combination of anti-
CD147 and CsA led to an inhibition of neutrophil infiltration only slightly greater than that
induced by the individual treatments. In the absence of a major additive effect from combining
the two intervention regimens, such findings suggest that anti-CD147 and CsA are probably
acting on the same cyclophilin-CD147 interactions. This is an important issue, because CD147
has also been reported to act as an adhesion molecule in vivo (18). Specifically, the capacity
of erythrocytes to circulate out of the spleen into the general circulation was significantly
impaired after treatment with anti-CD147. However, erythrocyte entry into tissues was not
affected, and there was no evidence of a selective retention of erythrocytes or leukocytes within
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other organs, suggesting that the adhesion properties of CD147 may be limited to specific
subsets of cells and tissues. In unrelated in vitro studies, recombinant cyclophilins have been
shown to increase leukocyte adhesion to an extracellular matrix (8). However, the mechanism
for this increased adhesion was dependent on interaction with glycosaminoglycans, rather than
CD147, and was restricted to CyPB. Thus, we think it unlikely that changes in the adhesive
properties of neutrophils, due to either cyclophilin-CD147 interactions or our intervention
regimens, are responsible for the observed changes in neutrophil accumulation within inflamed
tissues. Nevertheless, we acknowledge that changes in CD147-dependent adhesion cannot be
formally ruled out in our current in vivo studies and remain a possible contributing factor.
To date, there have been many reports of immune-mediated approaches to decrease neutrophil
extravasation and/or accumulation in tissues during inflammatory responses. Indeed, studies
have reported significant reductions in neutrophilia after the inhibition of different chemokines
or their receptors (19–22). Interestingly, regardless of the chemokine or receptor inhibited, the
influx of neutrophils into tissues was always reduced by at least 25%, and in many cases by
>50%. Given that the total contribution of all reported chemokines cannot be >100%, such
findings imply the existence of a chemokine network that is either sequentially or
synergistically regulated during acute inflammation. Alternatively, the contributions of some
of these chemokines might not be in the initiation of leukocyte recruitment, but, rather, in the
amplification of recruitment, the retention of leukocytes in inflamed tissues, and/or providing
survival signals for recruited cells. Where extracellular cyclophilins fit within this scheme is
unknown, but is currently under investigation. One preliminary observation is that intranasal
delivery of CyPA alone is not sufficient to initiate leukocyte influx into tissues (our unpublished
observations). Such a finding suggests that the contribution of extracellular cyclophilins during
inflammatory responses is dependent on an initial proinflammatory signal, as might be
provided by LPS, or on the presence of another factor released during the response.
Taken together, our findings strongly implicate a role for extracellular cyclophilins, via
interaction with CD147, on the accumulation of circulating leukocytes within sites of
inflammation and suggest that cyclophilin-CD147 interactions contribute directly to the
pathogenesis of inflammatory responses. Studies are underway to establish whether such
interactions also play a role in other inflammatory diseases, providing potentially novel
therapeutic targets for many inflammation-mediated diseases.
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FIGURE 1.
CD147 expression on murine leukocytes. A, Leukocytes obtained from peripheral blood of
C57BL/6 mice were stained with anti-CD147 mAb, or isotype control mAb, followed by FITC-
conjugated anti-rat IgG. Analysis gates were set on the lymphoid, monocytic, or granulocytic
population using forward scatter/side scatter distributions.■, Isotype control staining;□, CD147
expression. B, Neutrophils from different sites were compared for CD147 expression. Each
population was stained with anti-CD147 or isotype control mAb, followed by FITC-anti-rat
IgG. Neutrophils were identified by additional staining with PE-conjugated anti-GR-1 mAb.
Data show the expression of CD147 (□) relative to isotype control staining (■) after gating on
GR-1+ leukocytes.
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FIGURE 2.
Murine neutrophils migrate in response to CyPA in vitro. Neutrophils were enriched from the
peritoneal cavity of C57BL/6 mice and set up in 48-well Boyden chambers in the presence of
recombinant CyPA, FMLP (as a positive control), or medium alone. A, Different concentrations
of CyPA were compared, relative to 10−7 M FMLP. B, A dose of 100 ng/ml CyPA was used
with or without the addition of 25 µg/ml anti-CD147 or isotype control mAb. C, A dose of 100
ng/ml CyPA or 10−7 M FMLP was used with or without the addition of 25 µg/ml anti-CD147
or 2 µM nonimmunosuppressive CsA (SDZNIM811). Graphs show the mean (±SE)
chemotactic index (number of cells migrating in response to chemotactic agent divided by
number of cells migrating to medium alone) for each group (n = 4–6 wells/group). Student’s
t test was used to establish statistical significance between groups of wells treated with anti-
CD147 or CsA compared with CyPA alone: ***, p < 0.001.
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FIGURE 3.
Inflammation induced by intranasal LPS is associated with elevated cyclophilins in airways.
Groups (n = 5) of C57BL/6 mice were given PBS or 2 µg of LPS by intranasal delivery; 18 h
later, the animals were killed, and their BAL fluid was collected. A, For Western blot analysis,
BAL fluid was cleared of leukocytes by centrifugation and pooled within groups of mice.
Equivalent volumes of each pool were run under denaturing conditions by SDS-PAGE,
followed by transfer onto nylon membranes and then probing with rabbit-anti-CyPA. The
Western blot shows detection of CyPA in groups of mice from two or three individual
experiments. The standard was a lysate of HEK293T cells. B, Densitometry was conducted on
the individual lanes from the blot. Data show the mean gel band density (GBD) for the lanes
from PBS vs LPS groups. Student’s t test was used to establish statistical significance:*, p <
0.05. C, Neutrophil numbers were determined in each of the pooled BAL samples by staining
cell suspensions with PE-conjugated anti-GR-1, followed by FACS analysis. Data show a
correlation between the number of neutrophils recovered and the CyPA content (based on
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GBD) for each BAL sample. A correlation coefficient (r2) was calculated between the two
parameters.
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FIGURE 4.
Inhibition of cyclophilin-CD147 interactions by in vivo anti-CD147 treatment significantly
reduces tissue inflammation. A, Groups of C57BL/6 mice were given an i.p. injection of 100
µg of anti-CD147 or isotype control mAb 1 day before treatment with LPS and then a second
injection at the same time as intranasal delivery of LPS. At 18 h after LPS delivery, the mice
were killed, and their lung tissue and BAL fluid were collected. Tissue and BAL leukocytes
from individual mice were stained with PE-anti-GR-1 and analyzed by FACS. Data show the
mean number (±SE) of neutrophils detected in each group of mice (n = 7–9/group). Student’s
t test was used to establish statistical significance:***, p < 0.001; *, p < 0.05. B, In some studies
lung tissue was fixed in 10% formalin, sectioned, and stained with H&E for histological
analysis. Histology (×10 magnification) shows representative sections from the following
groups: a, PBS alone; b, LPS alone; c, LPS plus isotype treatment; d, LPS plus anti-CD147
treatment. Arrows denote foci of inflammation.
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FIGURE 5.
Inhibition of cyclophilins by in vivo CsA treatment significantly reduces tissue inflammation.
A, Groups of C75BL/6 mice were given an i.p. injection of 20 mg/kg body weight SDZNIM811
(or diluent alone), and 10 h later a second dose was given i.p. at the same time as intranasal
delivery of LPS. All groups were killed 18 h later, and lung tissue was isolated and stained
with PE-anti-GR-1 for FACS analysis. Data show the mean number (±SE) of neutrophils
detected in lung tissues of each group of mice (n = 5/group). B, Groups of mice were given
either two doses of 20 mg/kg SDZNIM811 (10 h before intranasal LPS and concurrently with
LPS), two doses of 100 µg of anti-CD147 mAb (1 day before intranasal LPS and concurrently
with LPS), or both treatments. All groups were killed 18 h later, and lung tissue was isolated
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and stained with PE-anti-GR-1 for FACS analysis. Data show the mean number (±SE) of
neutrophils detected in each group of mice (n = 8–10/group). For all studies, Student’s t test
was used to establish statistical significance: ***, p < 0.001;**, p < 0.01; *, p < 0.05.
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